Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with S-1-based adjuvant therapy after D2 resection for locally advanced gastric cancer
ChiCTR1900021412Phase 4Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib, tegafur and oxaliplatin in gastric cancer (GC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 3-year disease-free survival rate. Started Jan 2019; status: recruiting.
02
Drugs
Rivoceranibtegafuroxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1900021412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021412.